



This is a repository copy of *Sialylation inhibition can partially revert acquired resistance to enzalutamide in prostate cancer cells.*

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/216995/>

Version: Published Version

Article:

Goode, E.A., Orozco-Moreno, M. orcid.org/0000-0002-6180-7882, Hodgson, K. orcid.org/0000-0003-4348-0430 et al. (10 more authors) (2024) Sialylation inhibition can partially revert acquired resistance to enzalutamide in prostate cancer cells. *Cancers*, 16 (17). 2953. ISSN 2072-6694

<https://doi.org/10.3390/cancers16172953>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Article

Sialylation Inhibition Can Partially Revert Acquired Resistance to Enzalutamide in Prostate Cancer Cells

Emily Archer Goode¹, Margarita Orozco-Moreno¹ , Kirsty Hodgson¹ , Amirah Nabilah¹, Meera Murali¹, Ziqian Peng¹, Jona Merx², Emiel Rossing³ , Johan F. A. Pijnenborg³ , Thomas J. Boltje^{2,3}, Ning Wang^{4,5} , David J. Elliott¹ and Jennifer Munkley^{1,*} 

¹ Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle NE1 3BZ, UK; e.archer-goode@newcastle.ac.uk (E.A.G.); maggie.orozco-moreno@newcastle.ac.uk (M.O.-M.); kirsty.hodgson@newcastle.ac.uk (K.H.); a.nabilah2@newcastle.ac.uk (A.N.); m.murali2@newcastle.ac.uk (M.M.); z.peng9@newcastle.ac.uk (Z.P.); david.elliott@newcastle.ac.uk (D.J.E.)

² Synthetic Organic Chemistry, Institute for Molecules and Materials, Radboud University, 6525 XZ Nijmegen, The Netherlands; jona.merx@ru.nl (J.M.); thomas.boltje@ru.nl (T.J.B.)

³ GlycoTherapeutics B.V., 6511 AJ Nijmegen, The Netherlands; emiel.rossing@glycotherapeutics.eu (E.R.); johan.pijnenborg@glycotherapeutics.eu (J.F.A.P.)

⁴ The Mellanby Centre for Musculoskeletal Research, Division of Clinical Medicine, The University of Sheffield, Sheffield S10 2TN, UK; nw208@leicester.ac.uk

⁵ Leicester Cancer Research Centre, Department of Genetics and Genome Biology, University of Leicester, Leicester LE2 7LX, UK

* Correspondence: jennifer.munkley@ncl.ac.uk

Simple Summary: Prostate cancer is the most common cancer in men and a major cause of cancer-related deaths around the world. Prostate cancer that has spread to other parts of the body (advanced prostate cancer) is often treated with a drug called enzalutamide, which is a type of hormone therapy. Enzalutamide works by blocking the effect of the testosterone hormone on prostate cancer cells to stop them from growing. While this can be effective for several years, unfortunately, many patients being treated with enzalutamide eventually go on to become resistant to treatment, and the therapy stops working. Here, we show that prostate cancer cells that have become resistant to enzalutamide have increased levels of a type of sugar (known as sialic acid) on their surfaces. We set out to test whether stripping sialic acid from the surface of prostate cancer cells could help keep enzalutamide working for longer. Excitingly, our experiments show that treating prostate cancer cells with a drug to block sialic acid can partially reverse enzalutamide resistance. These findings suggest that drugs targeting sialic acid could be used in combination with enzalutamide therapy to disarm drug resistance and provide urgently needed new treatment options for men with prostate cancer.

Abstract: Prostate cancer is a lethal solid malignancy and a leading cause of cancer-related deaths in males worldwide. Treatments, including radical prostatectomy, radiotherapy, and hormone therapy, are available and have improved patient survival; however, recurrence remains a huge clinical challenge. Enzalutamide is a second-generation androgen receptor antagonist that is used to treat castrate-resistant prostate cancer. Among patients who initially respond to enzalutamide, virtually all acquire secondary resistance, and an improved understanding of the mechanisms involved is urgently needed. Aberrant glycosylation, and, in particular, alterations to sialylated glycans, have been reported as mediators of therapy resistance in cancer, but a link between tumour-associated glycans and resistance to therapy in prostate cancer has not yet been investigated. Here, using cell line models, we show that prostate cancer cells with acquired resistance to enzalutamide therapy have an upregulation of the sialyltransferase ST6 beta-galactoside alpha-2,6-sialyltransferase 1 (ST6GAL1) and increased levels of α 2,6-sialylated *N*-glycans. Furthermore, using the sialyltransferase inhibitor P-SiaFNEtocol, we discover that acquired resistance to enzalutamide can be partially reversed by combining enzalutamide therapy with sialic acid blockade. Our findings identify a potential role for ST6GAL1-mediated aberrant sialylation in acquired resistance to enzalutamide therapy for prostate cancer and suggest that sialic acid blockade in combination with enzalutamide may represent a novel



Citation: Goode, E.A.; Orozco-Moreno, M.; Hodgson, K.; Nabilah, A.; Murali, M.; Peng, Z.; Merx, J.; Rossing, E.; Pijnenborg, J.F.A.; Boltje, T.J.; et al. Sialylation Inhibition Can Partially Revert Acquired Resistance to Enzalutamide in Prostate Cancer Cells. *Cancers* **2024**, *16*, 2953. <https://doi.org/10.3390/cancers16172953>

Academic Editor: Fred Saad

Received: 18 July 2024

Revised: 8 August 2024

Accepted: 22 August 2024

Published: 24 August 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

therapeutic approach in patients with advanced disease. Our study also highlights the potential to bridge the fields of cancer biology and glycobiology to develop novel combination therapies for prostate cancer.

Keywords: prostate cancer; castrate resistance; enzalutamide; sialic acid; sialyltransferase inhibitor; combination therapies

1. Introduction

Prostate cancer is the second most common cancer in men worldwide and is a significant cause of morbidity and mortality in the global male population [1]. Although localised prostate cancer is largely curable and has a five-year survival rate of >99%, the mortality rate for advanced prostate cancer is high, and only 32% of advanced prostate cancer patients will be alive after 5 years [2]. Primary prostate cancer is largely driven through androgen signalling via interactions with the androgen receptor (AR) and is commonly therapeutically managed with androgen deprivation therapies (ADT) [3,4]. Although ADT achieves initial success, the majority of patients will develop resistance to these therapies within 5 years of diagnosis and will go on to develop castrate-resistant prostate cancer (CRPC), where tumours persist despite low androgen conditions due to the acquisition of resistance mechanisms [5,6]. Patients with CRPC are managed with second-generation androgen receptor inhibitors (enzalutamide, abiraterone, apalutamide, or darolutamide), radium-223 for bone metastases, immunotherapy (sipuleucel-T, pembrolizumab), poly-ADP ribose polymerase (PARP) inhibitors (olaparib, rucaparib), or chemotherapy (most commonly docetaxel) [2,7–11]. However, resistance to these interventions is commonplace, culminating in the median survival of 9–30 months for CRPC patients [2,12].

Enzalutamide (MDV3100, Xtandi[®]) is a commonly used second-generation AR inhibitor that demonstrates a higher affinity for binding to the AR in comparison to its predecessors, such as bicalutamide, and has the capacity to prevent AR nuclear translocation, DNA-binding, and recruitment of co-activators [13–18]. Clinical trial data have highlighted that the inclusion of enzalutamide in the clinical regimen for treating patients with CRPC could significantly improve overall survival and progression-free survival [13,15,19–21]. However, both primary and acquired resistance are observed in relation to enzalutamide treatment. Primary resistance to enzalutamide (defined as treatment failure within the first 3 months following treatment initiation) occurs in 25% of CRPC patients, and acquired resistance is typically observed 9–15 months following treatment initiation [14,22–24]. How CRPC tumours develop resistance to enzalutamide remains to be fully understood, but it likely includes AR amplification, AR mutations, the generation of AR splice variants (AR-v), alterations to steroidogenesis, overexpression of glucocorticoid and progesterone receptors, and neuroendocrine differentiation [14,22,25]. As most patients treated with enzalutamide eventually develop resistance and disease progression, there is a critical need to identify mechanisms of resistance as targets for future therapies [26,27].

Glycosylation is a post translational modification where glycan structures are added to proteins and lipids [28–30]. Altered glycosylation is a hallmark of cancer and can mediate critical events in tumour development and progression [31,32]. Even though aberrant glycosylation is a potentially druggable hallmark of cancer [28,33–35], to date, it has been relatively underexplored particularly in the context of prostate cancer. Studies have sought to understand the molecular mechanisms underpinning prostate cancer progression and resistance to therapy [36–40], but only a few have studied glycans. Historically, this has been due to technological limitations, but this is now changing. For example, the development of *N*-glycan imaging mass spectrometry [41–43] has enabled the profiling of glycosylation changes throughout prostate cancer evolution [44]. An understanding of the role glycans play in prostate cancer will be crucial to the identification of new targets that can be exploited to treat advanced disease and prolong patient survival [45–48]. Recent

studies have highlighted the potential to target aberrant glycosylation in combination with existing therapies to boost treatment response and potentially overcome therapy resistance [34,49,50] and this area of research is beginning to show promise for prostate cancer [51–54].

A common change in tumour glycosylation is alterations to sialylated glycans, and this can actively drive aggressive disease [55–58]. Aberrant sialylation has been linked to paclitaxel and cisplatin resistance in ovarian cancer [59–61], chemotherapy resistance in gastric cancer [62], sensitivity to docetaxel in hepatocarcinoma [63], multi-drug resistance in leukaemia [64,65], sensitivity to tyrosine kinase inhibition in lung cancer [66], and bortezomib resistance in myeloma [67]. A correlation between radiotherapy resistance and increased sialylation is also well established, particularly for colorectal cancer [68–71]. The contribution of sialylated glycans to chemotherapy resistance in cancer could be due to the physical barrier of extra sialic acid on the surface of cells which can potentially modify key receptors or block the uptake of drugs into the cell. For example, sialylation of the oncogenic receptor Erb2 can mask an epitope recognised by the anti-cancer antibody trastuzumab and promote resistance [72]. Sialylated glycans may also promote therapy resistance by absorbing ionising radiation [56], and radiation exposure can enhance the sialylation of membrane glycoproteins to promote radiation resistance [68,73]. Taken together, these studies raise the possibility of targeting aberrant sialylation in combination with existing cancer therapies to improve patient outcomes.

In prostate cancer, a rewiring of the tumour glycome is associated with disease progression, and glycans play important roles in tumour growth, metastasis, and immune evasion [45,48,74–76]. Recently, we showed that ST6 beta-galactoside alpha-2,6-sialyltransferase 1 (ST6GAL1) and larger branched sialylated *N*-glycans are upregulated in men with prostate cancer, and this can promote tumour growth and the spread of tumours to bone [52,77]. Aberrant sialylation is causally linked to therapy resistance in cancer [55], and ST6GAL1 has been identified as a mediator of treatment resistance in several tumour types, including pancreatic cancer [78], colorectal cancer [73,79], leukaemia [80,81], and gastric cancer [72]. A previous study showed resistance to hormonal therapy in prostate cancer is associated with an upregulation of complex larger-branched *N*-glycans [74]. However, to date, studies investigating the role of ST6GAL1 and its associated glycans in therapy-resistant prostate cancer are lacking.

Here, using VCaP and LNCaP cell line models, we show that prostate cancer cells with acquired resistance to enzalutamide have upregulated ST6GAL1 and significantly higher levels of α 2-6 sialylated *N*-glycans. Our findings identify ST6GAL1-mediated aberrant sialylation as a potential mediator of acquired resistance to enzalutamide therapy in prostate cancer. Furthermore, using the newly developed C-5 carbamate sialyltransferase inhibitor P-SiaFNEtoc [82,83], we show that acquired resistance to enzalutamide by prostate cancer cells can be partially reversed by sialic acid blockade. These results suggest that inhibiting sialylation in combination with enzalutamide may represent a novel therapeutic approach in patients with advanced prostate cancer.

2. Methods

2.1. Cell Culture

Cell culture was carried out as described previously [84]. VCaP (CRL-2876) and LNCaP (CRL-1740) cells were purchased from ATCC. Enzalutamide-resistant VCaP (VCaP^{EnzR}) and LNCaP (LNCaP^{EnzR}) cell lines were generated as described previously [85]. Briefly, LNCaP and VCaP cells were grown in 10 μ M enzalutamide in long-term culture (>6 months). Resistant cells were pooled and maintained. Once resistant, cells were continually cultured in 10 μ M enzalutamide. No changes in phenotype were observed, and we did not detect any genomic changes. The cell lines were authenticated using DNA STR analysis and tested every 3 months for mycoplasma contamination.

2.2. Inhibitors

The enzalutamide (MDV3100, Xtandi[®]) was purchased from MedChemExpress[®] (HY-70002). The sialyltransferase inhibitor P-SiaFNEtoc was synthesised as described previously [82] (compound 10).

2.3. Western Blotting

Western blotting was performed as previously described [86]. Immunoblots were probed with antibodies for ST6GAL1 at 1:1000 dilution (Abgent, San Diego, CA, USA, AP19891c) or GAPDH at 1:2000 dilution (Abgent, AP7873b), followed by incubation with appropriate fluorescent secondary antibodies at 1:10,000 dilution, (anti-mouse 680, Cell Signalling, Leiden, The Netherlands, 5470S) or anti-rabbit 800 (Cell Signalling, 5151S)).

2.4. ELISA Assays

Conditioned media samples were prepared from cell lines as described previously [86]. ST6GAL1 protein levels were monitored using sandwich ELISA assays, which have previously been validated (Cambridge Bioscience, Cambridge, UK, ELH-ST6GAL1-1) [77].

2.5. Immunocytochemistry

The cells were cultured in a Nunc[™] 4 well plate (Thermo Scientific[™], Oxford, UK, 176740) on top of a sterilised 10 mm-round coverslip (VWR[™], 631-1340) in complete media. Treatments with P-SiaFNEtoc were performed for either for 3 days (LNCaP cells) or 6 days (VCaP cells) with the indicated concentrations. Cells treated with DMSO were used as controls. The cells were washed with PBS before permeabilization and fixation with ice-cold absolute methanol for 10 min at -20°C . Next, the cells were washed with PBS and blocked with 10% goat serum (Abcam, Cambridge, UK, ab7481) for 1 h at room temperature. The cells were incubated overnight at 4°C with a ST6GAL1 antibody at 1:200 (Abgent, AP19891c), followed by goat anti-rabbit IgG H and L (Alexa Fluor[®] 594) (Abcam, ab150080), diluted 1:500. Finally, the cells were washed with PBS and stained with Hoechst (Thermo Scientific, 62249) for 15 min at room temperature. Images were acquired and processed with a ZEISS Axio Imager 4.

2.6. Lectin Immunofluorescence

The cells were cultured in a Nunc[™] 4-well plate (Thermo Scientific[™], 176740) on top of a sterilised 10 mm-round coverslip (VWR[™], 631-1340) in complete media. Treatments with P-SiaFNEtoc were performed for either for 3 days (LNCaP cells) or 6 days (VCaP cells) with the indicated concentrations. Cells treated with DMSO were used as controls. P-SiaFNEtoc concentrations were optimised to $2\ \mu\text{M}$ for 3 days and $20\ \mu\text{M}$ for 6 days for the LNCaP and VCaP cells, respectively. For neuraminidase treatment, α 2-3,6,8 neuraminidase (NEB, UK, P0720) was used as a negative control to strip sialic acid from the surface of the cells. The cells were cultured in 100 units/mL of neuraminidase as described previously [44]. To monitor Sambucas nigra (SNA) lectin binding, the cells were washed with PBS before permeabilization and fixation with ice-cold absolute methanol for 10 min at -20°C . Next, the cells were washed with PBS and blocked with 1X Carbo-Free[™] Blocking Solution (1X CFB) (Vector Laboratories, Cambs, UK, SP-5040-125) for 1 h at room temperature. The cells were incubated overnight at 4°C with FITC-conjugated SNA lectin (Vector Laboratories, FL-1301-2). Finally, the cells were washed with PBS and stained with Hoechst (Thermo Scientific, 62249) for 15 min at room temperature. The cells were mounted using ProLong[™] gold antifade mountant (Thermo Scientific[™], P36930), and images were acquired and processed with the ZEISS Axio Imager 4.

2.7. CellTiter-Glo[®] Assays

CellTiter-Glo[®] Luminescent cell viability assays (Promega, UK, G9682) were performed as described previously [51]. Cell viability was assessed at the times indicated, and luminescence was recorded with the Varioskan[™] LUX microplate reader.

VCaP cells: The VCaP control and VCaP^{EnzR} cells were seeded at a density of 7.0×10^3 cells/well in 96-well plates (Thermo scientific, 130188). After 24 h, the cells were treated with a range of concentrations of enzalutamide with or without concurrent treatment with 20 μ M P-SiaFNEtocol for 6 days (144 h).

LNCaP cells: The LNCaP control and LNCaP^{EnzR} cells were seeded at a density of 3.0×10^3 cells/well in a 96-well plate. After 24 h, the cells were treated with a range of enzalutamide concentrations with or without concurrent treatment with 2 μ M P-SiaFNEtocol for 3 days (72 h).

2.8. Statistical Analyses

Statistical analyses were conducted using the GraphPad Prism software (version Prism 9.4.1). Data are presented as the mean of three independent samples \pm standard error of the mean (SEM). Statistical significance is denoted as * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, and **** $p < 0.0001$.

3. Results

3.1. Prostate Cancer Cells with Acquired Enzalutamide Resistance Have Upregulated ST6GAL1

The sialyltransferase ST6GAL1 has been previously identified to be upregulated in prostate cancer and linked with tumour growth, metastasis, and poor overall survival [52,77,87,88]. ST6GAL1 has been reported as a mediator of therapy resistance in other cancer types [72,73,78–81], but a link between ST6GAL1 and resistance to therapy has not yet been investigated for prostate cancer. To address this gap, we used western blotting and pre-validated sandwich ELISA assays [77] to monitor ST6GAL1 protein levels in VCaP and LNCaP prostate cancer cell line models with acquired resistance to enzalutamide. Our findings show intracellular and secreted ST6GAL1 levels are upregulated in the enzalutamide-resistant VCaP cells (VCaP^{EnzR}), compared to the enzalutamide-sensitive control VCaP cells (Figure 1A,B). Upregulation of ST6GAL1 was also detected in the enzalutamide-resistant LNCaP cells (LNCaP^{EnzR}), where levels of ST6GAL1 are increased compared to the enzalutamide-sensitive control LNCaP cells (Figure 1C,D). Taken together, these findings suggest that the sialyltransferase ST6GAL1 is upregulated in prostate cancer cells with acquired resistance to enzalutamide therapy.




Figure 1. Enzalutamide-resistant prostate cancer cells have upregulation of ST6GAL1. (A) Western blot analysis of ST6GAL1 in the VCaP control and enzalutamide-resistant VCaP (VCaP^{EnzR}) cells.

ST6GAL1 levels are increased in both cell pellet and conditioned media samples from the VCaP^{EnzR} cells. GAPDH is included as a loading control. (B) Analysis of ST6GAL1 levels in conditioned media samples from the VCaP control and VCaP^{EnzR} cells using pre-validated sandwich ELISA assays [77]. The levels of ST6GAL1 are significantly higher in conditioned media from VCaP^{EnzR} cells (n = 3, unpaired *t*-test, *** *p* = 0.0002). (C) Western blot analysis of ST6GAL1 in the LNCaP control and enzalutamide-resistant LNCaP (LNCaP^{EnzR}) cells. GAPDH is used as a loading control. The levels of ST6GAL1 are increased in both cell pellet and conditioned media samples (D) Analysis of ST6GAL1 levels in conditioned media samples from the LNCaP control and LNCaP^{EnzR} cells using pre-validated sandwich ELISA assays [77]. The levels of ST6GAL1 are significantly higher in conditioned media from the LNCaP^{EnzR} cells compared to the control LNCaP cells (n = 6, unpaired *t*-test, ** *p* = 0.0014). Results are representative of three biological repeats and are presented as the mean ± standard error. Original western blots are presented in File S1.

3.2. Enzalutamide-Resistant Prostate Cancer Cells Have Increased Levels of α 2,6-Sialylated *N*-Glycans

ST6GAL1 adds α 2,6-linked sialic acid to *N*-glycosylated proteins that are destined for the cell membrane or secretion [55,89,90]. In previous studies, we detected increased levels of α 2,6 sialylation in prostate cancer cells with an upregulation of ST6GAL1 [52,77]. We thus hypothesised that the upregulation of ST6GAL1 in enzalutamide-resistant prostate cancer cells will alter the levels of α 2,6 sialylated *N*-glycans. To test this, we used immunofluorescence to monitor recognition by the SNA lectin (which recognises α 2,6-linked sialylated *N*-glycans [91]) in prostate cancer cells with acquired resistance to enzalutamide. Our findings show that the VCaP^{EnzR} cells have increased binding of SNA lectin relative to the control enzalutamide-sensitive VCaP cells (Figure 2A). Similarly, the LNCaP^{EnzR} cells also show increased recognition by SNA lectin, indicating increased levels of α 2,6 sialylation in these cells compared to the control enzalutamide-sensitive LNCaP cells (Figure 2B). Confirming the specificity of our results, SNA binding was eliminated when cells were treated with neuraminidase (which removes terminal sialic acids of glycans) (Supplementary Figure S1). In summary, these findings suggest enzalutamide resistance correlates with an upregulation of α 2,6-sialylated *N*-glycans in prostate cancer cell line models.




Figure 2. Enzalutamide-resistant prostate cancer cells have upregulation of ST6GAL1 and increased levels of α 2,6-sialylated glycans. (A) SNA lectin immunofluorescence shows VCaP^{EnzR} cells have

increased levels of ST6GAL1 and α 2-6 sialylation (SNA, the lectin from *Sambucus nigra*, recognises α 2-6-linked sialylated N-glycans [91]). (B) SNA lectin immunofluorescence shows LNCaP^{EnzR} cells have increased levels of ST6GAL1 and α 2-6 sialylation compared to control LNCaP cells. DNA is stained with Hoechst. Scale bar = 200 μ M.

3.3. The Sialyltransferase Inhibitor P-SiaFNEtocol Blocks α 2,6 Sialylation in Enzalutamide-Resistant Prostate Cancer Cells

We previously showed that the newly developed C-5 carbamate sialyltransferase inhibitor P-SiaFNEtocol [82] can effectively inhibit the sialylation of prostate cancer cells with only minor effects on other glycan types [51]. Next, to test whether P-SiaFNEtocol can inhibit α 2,6-sialylated N-glycans in enzalutamide-resistant prostate cancer cells, we treated VCaP^{EnzR} and LNCaP^{EnzR} cells with P-SiaFNEtocol and monitored α 2,6-sialylation using SNA lectin immunofluorescence after 3 or 6 days (Supplementary Figure S2). For the VCaP^{EnzR} cells, treatment with 20 μ M P-SiaFNEtocol for 6 days suppressed recognition by SNA lectin, suggesting a reduction in α 2,6-sialylated N-glycans (Figure 3A). For the LNCaP^{EnzR} cells, treatment with 2 μ M P-SiaFNEtocol for 3 days reduced levels of levels of α 2,6 sialylation (Figure 3B). As VCaP cells have a significantly longer doubling time than LNCaP cells [92,93], and have higher endogenous levels of ST6GAL1 [87], we hypothesised that this may explain why the VCaP cells required increased concentrations of P-SiaFNEtocol to reduce α 2,6-sialylation levels, but we did not investigate this further. Together with previously published findings [51], our data show that treatment with the sialyltransferase inhibitor P-SiaFNEtocol can block α 2,6 sialylation in enzalutamide-resistant prostate cancer cells.




Figure 3. Cont.




Figure 3. The sialyltransferase inhibitor P-SiaFNEt oc blocks α 2,6 sialylation in the VCaP^{EnzR} and LNCaP^{EnzR} prostate cancer cells. (A) Detection of immunofluorescent staining of ST6GAL1 and α 2,6-sialylation of N-glycans in the VCaP control and VCaP^{EnzR} cells treated with 20 μ M of the sialyltransferase inhibitor P-SiaFNEt oc for 6 days. Treatment of both cell lines with P-SiaFNEt oc inhibits α 2,6-sialylation of N-glycans (detected using SNA lectin). Control cells were treated with DMSO. Scale bar = 50 μ m. The images are representative of three biological repeats. (B) Detection of immunofluorescent staining of ST6GAL1 and α 2,6-sialylation of N-glycans in LNCaP control and LNCaP^{EnzR} cells treated with 2 μ M of the sialyltransferase inhibitor P-SiaFNEt oc for 3 days. Treatment of both cell lines with P-SiaFNEt oc inhibits α 2,6-sialylation of N-glycans (detected using SNA lectin). The control cells were treated with DMSO. Scale bar = 50 μ m. The images are representative of three biological repeats.

3.4. Sialic Acid Blockade Partially Reverts Acquired Resistance to Enzalutamide in Prostate Cancer Cells

Together with the literature [59–72], the above data raises the possibility that aberrant sialylation could play a functional role in the acquired resistance of prostate cancer to the second-generation AR antagonist enzalutamide. This led to the hypothesis that therapies targeting sialylation might have the potential to re-sensitise prostate cancer cells to treatment with enzalutamide. To investigate this, we first treated control VCaP and VCaP^{EnzR} cells with a range of enzalutamide concentrations (up to 500 μ M) and measured cellular viability using CellTiter-Glo[®] luminescence assays and IC₅₀ analyses. As expected, the IC₅₀ value for the VCaP^{EnzR} cells treated with enzalutamide was 3.46-fold higher relative to the control VCaP cells (VCaP control IC₅₀: 8.95 μ M, VCaP^{EnzR} IC₅₀: 30.97 μ M) (Figure 4A). Next, to test if sialic acid blockade can impact the resistance of prostate cancer cells to enzalutamide, we treated the VCaP^{EnzR} cells with enzalutamide in combination with the sialylation inhibitor P-SiaFNEt oc (treatments for VCaP cells were carried out with 20 μ M P-SiaFNEt oc for 6 days to match our findings in Figure 3A). Excitingly, this revealed that although sialic acid blockade in combination with enzalutamide therapy did not alter

the IC_{50} value for the VCaP control cell line, for the VCaP^{EnzR} cells, there was a 38.33% reversion in the IC_{50} value in comparison to enzalutamide treatment alone (VCaP control IC_{50} : 8.30 μ M, VCaP^{EnzR} IC_{50} : 19.10 μ M) (Figure 4B).




Figure 4. Sialic acid blockade using P-SiaFNEtocol partially re-sensitises prostate cancer cells to the second-generation androgen receptor antagonist enzalutamide. **(A)** The VCaP^{EnzR} cells have increased resistance to enzalutamide compared to the control VCaP cells. The control VCaP and VCaP^{EnzR} cells were treated with a range of enzalutamide concentrations (0–500 μ M). Cell viability was measured after 6 days using a CellTiter-Glo[®] luminescence assay. The IC_{50} values (the concentration of enzalutamide which reduced cellular viability by 50% relative to the DMSO control) was 3.46-fold greater in the VCaP^{EnzR} cells (8.95 μ M for VCaP control cells and 30.97 μ M for the VCaP^{EnzR} cells). **(B)** Treatment of the VCaP^{EnzR} cells with P-SiaFNEtocol partially reverts resistance to enzalutamide. The control VCaP and VCaP^{EnzR} cells were treated with 20 μ M P-SiaFNEtocol and a range of concentrations of enzalutamide (0–500 μ M) for 6 days. Inhibiting sialylation in the VCaP^{EnzR} cells reduced the IC_{50} value from 30.97 μ M to 19.10 μ M, indicating a partial reversion of their resistance to enzalutamide. **(C)** The LNCaP^{EnzR} cells have increased resistance to enzalutamide compared to the control LNCaP cells. The control LNCaP and LNCaP^{EnzR} cells were treated with a range of enzalutamide concentrations (0–500 μ M). Cell viability was measured after 3 days using a CellTiter-Glo[®] luminescence assay. The IC_{50} value was 2.27-fold higher in the LNCaP^{EnzR} cells (53.33 μ M for LNCaP control cells and 121.06 μ M for the LNCaP^{EnzR} cells). **(D)** Treatment of the LNCaP^{EnzR} cells with P-SiaFNEtocol partially reverts their resistance to enzalutamide. The control LNCaP and LNCaP^{EnzR} cells were treated with 2 μ M P-SiaFNEtocol and a range of concentrations of enzalutamide (0–500 μ M) for 3 days. A DMSO-only control arm was included for each cell line. Inhibiting sialylation in the LNCaP^{EnzR} cells reduced the IC_{50} value from 121.06 μ M to 74.30 μ M, indicating a partial reversion of their resistance to enzalutamide. A line of best fit was utilised for interpolating the IC_{50} value. Results are presented as the cell viability (luminescence) relative to the respective DMSO control against the log of the enzalutamide concentration (nM) used for each cell line. Results are presented as the mean \pm standard error and are representative of three biological repeats.

The IC₅₀ value for the LNCaP^{EnzR} cells was 2.27-fold higher relative to the control LNCaP cells when treated with enzalutamide alone (LNCaP control: 53.33 µM, LNCaP^{EnzR}: 121.06 µM) (Figure 4C). When the LNCaP^{EnzR} cells were treated with both P-SiaFNEtoc and enzalutamide (treatments for the LNCaP cells were carried out with 2 µM P-SiaFNEtoc for 3 days to match our findings in Figure 3B), there was a 38.64% reversion in the IC₅₀ value in comparison to enzalutamide treatment alone (LNCaP control IC₅₀: 59.16 µM, LNCaP^{EnzR} IC₅₀: 74.30 µM) (Figure 4C,D). These data indicate that that sialic acid blockade, in combination with enzalutamide treatment, can partially revert acquired enzalutamide resistance in cell line models of prostate cancer.

4. Discussion

Enzalutamide is an orally administered small-molecule inhibitor of the AR that is designed to overcome resistance to anti-androgens and can improve overall survival in CRPC [19,20,94]. Unfortunately, some patients have primary resistance to enzalutamide, and others eventually develop acquired resistance and continue to progress [27,95]. Numerous studies have sought to characterise the molecular mechanisms underlying how prostate cancer becomes resistant to enzalutamide therapy, with AR amplification, AR variants, altered expression of AR co-regulators, upregulation of glucocorticoid receptor (GR), and metabolic alterations believed to play a role [95,96]. ST6GAL1 and its associated glycans are likely to be an important target in cancer cells [89,90]. ST6GAL1 is upregulated in numerous types of cancer, including pancreatic, ovarian, breast, and prostate cancer, and its expression is associated with aggressive tumours and reduced survival times [52,89,97,98]. Upregulation of ST6GAL1 impacts oncogenic cell behaviours and can play a key role in tumour growth, survival, metastasis, immune evasion, and resistance to therapy [89,97,99]. Specifically, ST6GAL1 can mediate resistance to chemoradiation in rectal cancer [73], the sensitivity of gastric cancer cells to trastuzumab [72], and resistance to the EGFR inhibitor, gefitinib, in ovarian cancer [100]. In prostate cancer, the upregulation of ST6GAL1 promotes the growth and metastatic spread of prostate tumours to bone [52,77], and targeting aberrant sialylation in prostate cancer cells can inhibit the metastatic spread of tumours to bone [51,52]. The data presented in this manuscript indicate that ST6GAL1-mediated aberrant sialylation could also be an important mediator of the acquired resistance of prostate tumours to enzalutamide therapy (which is a major clinical issue potentially affecting all men who develop CRPC [101]. Furthermore, our study provides proof-of-concept data for a therapeutic strategy to target aberrant sialylation that has the potential to partially revert enzalutamide resistance and prolong the clinical efficacy of anti-androgen therapies. It should be noted that the sialyltransferase inhibitor used in this study (P-SiaFNEtoc) is a global sialyltransferase inhibitor that targets all sialyltransferase enzymes (including ST6GAL1), meaning we cannot rule out that the effects of P-SiaFNEtoc on the enzalutamide-resistant cells may not be solely due to ST6GAL1 inhibition. Inhibitors specifically targeting ST6GAL1 are being developed [56,102] and, once available, will be highly relevant to prostate cancer.

The mechanisms underpinning how aberrant sialylation might contribute to enzalutamide resistance in prostate cancer remain unclear but are likely multi-faceted. Aberrant sialylation on the cell surface could potentially inhibit the uptake of enzalutamide into the cell. Another possibility is that alterations to sialylated glycans could interfere with the binding of enzalutamide to the AR to promote resistance. The role of sialic acid in the context of the tumour microenvironment and immune suppression is also an important consideration which was not addressed by the current study. Increased sialylation is common in cancer cells and is associated with an immunosuppressed tumour microenvironment [57,99,103,104]. Sialylated glycans can be engaged by a broad range of immune cell types to promote immune suppression [105,106], and the upregulation of ST6GAL1 in prostate cancer cells has been shown to promote a shift towards an immunosuppressive M2 macrophage phenotype [52]. Anti-androgen therapies are known to remodel the prostate tumour immune microenvironment [107,108], and, recently, it was proposed that this re-

modelling could include alterations to the Siglec–sialoglycan axis in prostate tumours, which could contribute to immunosuppression [109]. Moving forward, syngeneic models of prostate cancer could be used to perform pre-clinical evaluation of sialic acid blockade in combination with enzalutamide therapy, alongside investigating the role of altered glycosylation in the resistance to enzalutamide therapy in the context of the tumour-immune microenvironment. Previous studies have identified increased levels of ST6GAL1 in tumours and blood samples from prostate cancer patients [52,77]. In future studies, it will be important to monitor the levels of ST6GAL1 and sialylated glycans in clinical samples from prostate cancer patients with tumours that have become resistant to enzalutamide therapy and investigate whether the detection of ST6GAL1 and/or aberrant sialylation in prostate tumours could be used to predict sensitivity and resistance to treatment strategies.

5. Conclusions

Our findings identify aberrant sialylation as a previously unexplored but clinically relevant contributor to the acquired resistance of prostate tumours to enzalutamide therapy and suggest further research in this area could lead to the development of novel combination therapies to disarm drug resistance in prostate cancer. Recent studies have provided rationale for the use of glyco-immune checkpoint-targeting therapies in advanced prostate cancer [52,109]. Numerous strategies to target sialylated glycans are under development, including sialylation inhibitors and antibody–sialidase conjugates [34,50,110], some of which are currently in clinical trials [34,50] and are likely to be relevant for patients with prostate cancer. Future research should seek to utilise these advancements in the glycobiology field to gain a better understanding of the role which aberrant glycosylation may play in prostate cancer resistance to key therapeutic interventions, such as enzalutamide.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/cancers16172953/s1>, Figure S1: SNA binding was eliminated when prostate cancer cells were treated with neuraminidase; Figure S2: Detection of α 2,6 sialylation in VCaP cells treated with 2–20 μ M P-SiaFNEtoc. File S1: Original western blots.

Author Contributions: Conceptualization, E.A.G., J.F.A.P., T.J.B. and J.M. (Jennifer Munkley); formal analysis, E.A.G., M.O.-M., K.H., A.N. and M.M.; funding acquisition, N.W.; investigation, E.A.G., M.O.-M., K.H., A.N., M.M. and Z.P.; methodology, E.A.G. and E.R.; resources, J.M. (Jona Merx), E.R., J.F.A.P. and T.J.B.; supervision, T.J.B., N.W., D.J.E. and J.M. (Jennifer Munkley); writing—original draft, E.A.G. and D.J.E.; writing—review and editing, K.H., N.W. and J.M. (Jennifer Munkley). All authors have read and agreed to the published version of the manuscript.

Funding: This work was funded by the Medical Research Council [MR/N013840/1, MR/R015902/1], Prostate Cancer Research and the Mark Foundation for Cancer Research (grant references 6961 and 6974), Prostate Cancer UK and The Bob Willis Fund through Research Innovation Awards [RIA16-ST2-011 and RIA21-ST2-006] and Newcastle University Hospitals Special Trustees. This work was supported by an ERC-Stg. (GlycoEdit, 758913) awarded to T.J.B.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The authors confirm that the data supporting the findings of this study are available within the article and its Supplementary Materials.

Conflicts of Interest: J.M. (Jennifer Munkley) is a shareholder of GlycoScoreDx Ltd. J.F.A.P. and E.R. are shareholders of and employed by GlycoTherapeutics B.V. T.J.B. is a shareholder of and scientific advisor of GlycoTherapeutics B.V.; J.F.A.P. and T.J.B. are shareholders of Synvenio B.V.; Radboud University and Radboudumc have filed patent applications related to P-SiaFNEtoc. All other authors declare that there are no potential competing interests.

References

1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* **2018**, *68*, 394–424. [[CrossRef](#)] [[PubMed](#)]
2. Archer Goode, E.; Wang, N.; Munkley, J. Prostate cancer bone metastases biology and clinical management (Review). *Oncol. Lett.* **2023**, *25*, 163. [[CrossRef](#)]
3. Fujita, K.; Nonomura, N. Role of Androgen Receptor in Prostate Cancer: A Review. *World J. Mens Health* **2019**, *37*, 288–295. [[CrossRef](#)] [[PubMed](#)]
4. Narayan, V.; Ross, A.E.; Parikh, R.B.; Nohria, A.; Morgans, A.K. How to Treat Prostate Cancer With Androgen Deprivation and Minimize Cardiovascular Risk: A Therapeutic Tightrope. *JACC CardioOncol.* **2021**, *3*, 737–741. [[CrossRef](#)]
5. Kirby, M.; Hirst, C.; Crawford, E.D. Characterising the castration-resistant prostate cancer population: A systematic review. *Int. J. Clin. Pract.* **2011**, *65*, 1180–1192. [[CrossRef](#)]
6. Nanda, J.S.; Koganti, P.; Perri, G.; Ellis, L. Phenotypic Plasticity-Alternate Transcriptional Programs Driving Treatment Resistant Prostate Cancer. *Crit. Rev. Oncog.* **2022**, *27*, 45–60. [[CrossRef](#)]
7. Rice, M.A.; Malhotra, S.V.; Stoyanova, T. Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer. *Front. Oncol.* **2019**, *9*, 801. [[CrossRef](#)]
8. Vellky, J.E.; Ricke, W.A. Development and prevalence of castration-resistant prostate cancer subtypes. *Neoplasia* **2020**, *22*, 566–575. [[CrossRef](#)]
9. Adashek, J.J.; Jain, R.K.; Zhang, J. Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer. *Cells* **2019**, *8*, 860. [[CrossRef](#)]
10. Aly, M.; Leval, A.; Schain, F.; Liwing, J.; Lawson, J.; Vágó, E.; Nordström, T.; Andersson, T.M.-L.; Sjöland, E.; Wang, C.; et al. Survival in patients diagnosed with castration-resistant prostate cancer: A population-based observational study in Sweden. *Scand. J. Urol.* **2020**, *54*, 115–121. [[CrossRef](#)]
11. Amaral, T.M.; Macedo, D.; Fernandes, I.; Costa, L. Castration-resistant prostate cancer: Mechanisms, targets, and treatment. *Prostate Cancer* **2012**, *2012*, 327253. [[CrossRef](#)] [[PubMed](#)]
12. Tran, C.; Ouk, S.; Clegg, N.J.; Chen, Y.; Watson, P.A.; Arora, V.; Wongvipat, J.; Smith-Jones, P.M.; Yoo, D.; Kwon, A.; et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. *Science* **2009**, *324*, 787–790. [[CrossRef](#)]
13. Shore, N.D.; Chowdhury, S.; Villers, A.; Klotz, L.; Siemens, D.R.; Phung, D.; van Os, S.; Hasabou, N.; Wang, F.; Bhattacharya, S.; et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): A randomised, double-blind, phase 2 study. *Lancet Oncol.* **2016**, *17*, 153–163. [[CrossRef](#)]
14. Dong, L.; Zieren, R.C.; Xue, W.; de Reijke, T.M.; Pienta, K.J. Metastatic prostate cancer remains incurable, why? *Asian J. Urol.* **2019**, *6*, 26–41. [[CrossRef](#)]
15. Cicero, G.D.E.L.; Dorangricchia, P.; Dieli, F. The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study. *Anticancer. Res.* **2017**, *37*, 1475–1480. [[PubMed](#)]
16. Linder, S.; van der Poel, H.G.; Bergman, A.M.; Zwart, W.; Prekovic, S. Enzalutamide therapy for advanced prostate cancer: Efficacy, resistance and beyond. *Endocr. Relat. Cancer* **2018**, *26*, R31–R52. [[CrossRef](#)] [[PubMed](#)]
17. Schalken, J.; Fitzpatrick, J.M. Enzalutamide: Targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. *BJU Int.* **2015**, *117*, 215–225. [[CrossRef](#)]
18. Hoffman-Censits, J.; Kelly, W.K. Enzalutamide: A novel antiandrogen for patients with castrate-resistant prostate cancer. *Clin. Cancer Res.* **2013**, *19*, 1335–1339. [[CrossRef](#)] [[PubMed](#)]
19. Scher, H.I.; Fizazi, K.; Saad, F.; Taplin, M.-E.; Sternberg, C.N.; Miller, K.; De Wit, R.; Mulders, P.; Chi, K.N.; Shore, N.D.; et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. *N. Engl. J. Med.* **2012**, *367*, 1187–1197. [[CrossRef](#)]
20. Beer, T.M.; Armstrong, A.J.; Rathkopf, D.E.; Loriot, Y.; Sternberg, C.N.; Higano, C.S.; Iversen, P.; Bhattacharya, S.; Carles, J.; Chowdhury, S.; et al. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. *N. Engl. J. Med.* **2014**, *371*, 424–433. [[CrossRef](#)]
21. Penson, D.F.; Armstrong, A.J.; Concepcion, R.; Agarwal, N.; Olsson, C.; Karsh, L.; Dunshee, C.; Wang, F.; Wu, K.; Krivoshik, A.; et al. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. *J. Clin. Oncol.* **2016**, *34*, 2098–2106. [[CrossRef](#)]
22. Tucci, M.; Zichi, C.; Buttigliero, C.; Vignani, F.; Scagliotti, G.V.; Di Maio, M. Enzalutamide-resistant castration-resistant prostate cancer: Challenges and solutions. *Onco Targets Ther.* **2018**, *11*, 7353–7368. [[CrossRef](#)]
23. Wang, Y.; Chen, J.; Wu, Z.; Ding, W.; Gao, S.; Gao, Y.; Xu, C. Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. *Br. J. Pharmacol.* **2020**, *178*, 239–261. [[CrossRef](#)]
24. Lin, H.-M.; Mak, B.; Yeung, N.; Huynh, K.; Meikle, T.G.; Mellett, N.A.; Kwan, E.M.; Fettke, H.; Tran, B.; Davis, I.D.; et al. Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. *EBioMedicine* **2021**, *72*, 103625. [[CrossRef](#)] [[PubMed](#)]
25. Claessens, F.; Helsen, C.; Prekovic, S.; Broeck, T.V.D.; Spans, L.; Van Poppel, H.; Joniau, S. Emerging mechanisms of enzalutamide resistance in prostate cancer. *Nat. Rev. Urol.* **2014**, *11*, 712–716. [[CrossRef](#)]
26. Hussain, A.; Dawson, N. Management of advanced/metastatic prostate cancer: 2000 update. *Oncology* **2000**, *14*, 1677–1688; discussion 1688, 1691–1694. [[PubMed](#)]

27. Blatt, E.B.; Raj, G.V. Molecular mechanisms of enzalutamide resistance in prostate cancer. *Cancer Drug Resist.* **2019**, *2*, 189–197. [[CrossRef](#)]
28. Pinho, S.S.; Reis, C.A. Glycosylation in cancer: Mechanisms and clinical implications. *Nat. Rev. Cancer* **2015**, *15*, 540–555. [[CrossRef](#)] [[PubMed](#)]
29. Eichler, J. Protein glycosylation. *Curr. Biol.* **2019**, *29*, R229–R231. [[CrossRef](#)]
30. Reily, C.; Stewart, T.J.; Renfrow, M.B.; Novak, J. Glycosylation in health and disease. *Nat. Rev. Nephrol.* **2019**, *15*, 346–366. [[CrossRef](#)]
31. Munkley, J.; Elliott, D.J. Hallmarks of glycosylation in cancer. *Oncotarget* **2016**, *7*, 35478–35489. [[CrossRef](#)] [[PubMed](#)]
32. Vajaria, B.N.; Patel, P.S. Glycosylation: A hallmark of cancer? *Glycoconj. J.* **2017**, *34*, 147–156. [[CrossRef](#)] [[PubMed](#)]
33. Thomas, D.; Rathinavel, A.K.; Radhakrishnan, P. Altered glycosylation in cancer: A promising target for biomarkers and therapeutics. *Biochim. Biophys. Acta Rev. Cancer* **2021**, *1875*, 188464. [[CrossRef](#)] [[PubMed](#)]
34. Mereiter, S.; Balmaña, M.; Campos, D.; Gomes, J.; Reis, C.A. Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading? *Cancer Cell* **2019**, *36*, 6–16. [[CrossRef](#)]
35. Rodrigues, J.G.; Duarte, H.O.; Reis, C.A.; Gomes, J. Aberrant protein glycosylation in cancer: Implications in targeted therapy. *Biochem. Soc. Trans.* **2021**, *49*, 843–854. [[CrossRef](#)]
36. Sinha, A.; Huang, V.; Livingstone, J.; Wang, J.; Fox, N.S.; Kurganovs, N.; Ignatchenko, V.; Fritsch, K.; Donmez, N.; Heisler, L.E.; et al. The Proteogenomic Landscape of Curable Prostate Cancer. *Cancer Cell* **2019**, *35*, 414–427 e6. [[CrossRef](#)]
37. Cheng, Q.; Butler, W.; Zhou, Y.; Zhang, H.; Tang, L.; Perkinson, K.; Chen, X.; Jiang, X.; McCall, S.J.; Inman, B.A.; et al. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy. *Eur. Urol.* **2022**, *81*, 446–455. [[CrossRef](#)]
38. Ren, S.; Shao, Y.; Zhao, X.; Hong, C.S.; Wang, F.; Lu, X.; Li, J.; Ye, G.; Yan, M.; Zhuang, Z.; et al. Integration of Metabolomics and Transcriptomics Reveals Major Metabolic Pathways and Potential Biomarker Involved in Prostate Cancer. *Mol. Cell Proteom.* **2016**, *15*, 154–163. [[CrossRef](#)]
39. Le, T.K.; Duong, Q.H.; Baylot, V.; Fargette, C.; Baboudjian, M.; Colleaux, L.; Taïeb, D.; Rocchi, P. Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments. *Cancers* **2023**, *15*, 5047. [[CrossRef](#)]
40. Karantanos, T.; Corn, P.G.; Thompson, T.C. Prostate cancer progression after androgen deprivation therapy: Mechanisms of castrate resistance and novel therapeutic approaches. *Oncogene* **2013**, *32*, 5501–5511. [[CrossRef](#)]
41. Powers, T.W.; Neely, B.A.; Shao, Y.; Tang, H.; Troyer, D.A.; Mehta, A.S.; Haab, B.B.; Drake, R.R. MALDI imaging mass spectrometry profiling of N-glycans in formalin-fixed paraffin embedded clinical tissue blocks and tissue microarrays. *PLoS ONE* **2014**, *9*, e106255. [[CrossRef](#)] [[PubMed](#)]
42. Drake, R.R.; Powers, T.W.; Norris-Caneda, K.; Mehta, A.S.; Angel, P.M. In Situ Imaging of N-Glycans by MALDI Imaging Mass Spectrometry of Fresh or Formalin-Fixed Paraffin-Embedded Tissue. *Curr. Protoc. Protein Sci.* **2018**, *94*, e68. [[CrossRef](#)] [[PubMed](#)]
43. West, C.A.; Liang, H.; Drake, R.R.; Mehta, A.S. New Enzymatic Approach to Distinguish Fucosylation Isomers of N-Linked Glycans in Tissues Using MALDI Imaging Mass Spectrometry. *J. Proteome Res.* **2020**, *19*, 2989–2996. [[CrossRef](#)]
44. Wallace, E.N.; West, C.A.; McDowell, C.T.; Lu, X.; Bruner, E.; Mehta, A.S.; Aoki-Kinoshita, K.F.; Angel, P.M.; Drake, R.R. An N-glycome tissue atlas of 15 human normal and cancer tissue types determined by MALDI-imaging mass spectrometry. *Sci. Rep.* **2024**, *14*, 489. [[CrossRef](#)]
45. Scott, E.; Munkley, J. Glycans as Biomarkers in Prostate Cancer. *Int. J. Mol. Sci.* **2019**, *20*, 1389. [[CrossRef](#)] [[PubMed](#)]
46. Munkley, J.; Mills, I.G.; Elliott, D.J. The role of glycans in the development and progression of prostate cancer. *Nat. Rev. Urol.* **2016**, *13*, 324–333. [[CrossRef](#)]
47. Kałuża, A.; Szczykutowicz, J.; Ferens-Sieczkowska, M. Glycosylation: Rising Potential for Prostate Cancer Evaluation. *Cancers* **2021**, *13*, 3726. [[CrossRef](#)]
48. Butler, W.; Huang, J. Glycosylation Changes in Prostate Cancer Progression. *Front. Oncol.* **2021**, *11*, 809170. [[CrossRef](#)]
49. Costa, A.F.; Campos, D.; Reis, C.A.; Gomes, C. Targeting Glycosylation: A New Road for Cancer Drug Discovery. *Trends Cancer* **2020**, *6*, 757–766. [[CrossRef](#)]
50. Smith, B.A.H.; Bertozzi, C.R. The clinical impact of glycobiology: Targeting selectins, Siglecs and mammalian glycans. *Nat. Rev. Drug Discov.* **2021**, *20*, 217–243. [[CrossRef](#)]
51. Orozco-Moreno, M.; Visser, E.A.; Hodgson, K.; Hipgrave Ederveen, A.L.; Bastian, K.; Goode, E.A.; Öztürk, Ö.; Pijnenborg, J.F.A.; Eerden, N.; Moons, S.J.; et al. Targeting aberrant sialylation and fucosylation in prostate cancer cells using potent metabolic inhibitors. *Glycobiology* **2023**, *33*, 1155–1171. [[CrossRef](#)]
52. Hodgson, K.; Orozco-Moreno, M.; Goode, E.A.; Fisher, M.; Garnham, R.; Beatson, R.; Turner, H.; Livermore, K.; Zhou, Y.; Wilson, L.; et al. Sialic acid blockade inhibits the metastatic spread of prostate cancer to bone. *EBioMedicine* **2024**, *104*, 105163. [[CrossRef](#)]
53. Wen, R.; Stark, J.; Marti, G.E.; Riley, N.; Zhao, H.; Bertozzi, C.R.; Pitteri, S.; Brooks, J.D. 517 Blocking Siglec-7/9-sialic acid interactions induces immune cell-mediated suppression of prostate cancer. *J. Immunotherapy Cancer* **2023**, *11* (Suppl. 1), A583.
54. Wen, R.; Marti, G.E.; Stark, J.; Marques, F.J.G.; Riley, N.; Bermudez, A.; Zhao, H.; Bertozzi, C.; Pitteri, S.; Brooks, J. Abstract 7524: Targeting siglec-7/9 glyco-immune checkpoints in prostate cancer for enhanced immune responses and tumor suppression. *Cancer Res.* **2024**, *84* (Suppl. 6), 7524. [[CrossRef](#)]
55. Munkley, J. Aberrant Sialylation in Cancer: Therapeutic Opportunities. *Cancers* **2022**, *14*, 4248. [[CrossRef](#)]

56. Dobie, C.; Skropeta, D. Insights into the role of sialylation in cancer progression and metastasis. *Br. J. Cancer* **2020**, *124*, 76–90. [[CrossRef](#)]
57. Huang, J.; Huang, J.; Zhang, G. Insights into the Role of Sialylation in Cancer Metastasis, Immunity, and Therapeutic Opportunity. *Cancers* **2022**, *23*, 5840. [[CrossRef](#)]
58. Jastrzab, P.; Narejko, K.; Car, H.; Wielgat, P. Cell Membrane Sialome: Sialic Acids as Therapeutic Targets and Regulators of Drug Resistance in Human Cancer Management. *Cancers* **2023**, *15*, 5103. [[CrossRef](#)]
59. Wu, X.; Zhao, J.; Ruan, Y.; Sun, L.; Xu, C.; Jiang, H. Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-beta1-induced EMT and confers paclitaxel resistance in ovarian cancer. *Cell Death Dis.* **2018**, *9*, 1102. [[CrossRef](#)]
60. Schultz, M.J.; Swindall, A.F.; Wright, J.W.; Sztul, E.S.; Landen, C.N.; Bellis, S.L. ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells. *J. Ovarian Res.* **2013**, *6*, 25. [[CrossRef](#)]
61. Ou, L.; He, X.; Liu, N.; Song, Y.; Li, J.; Gao, L.; Huang, X.; Deng, Z.; Wang, X.; Lin, S. Sialylation of FGFR1 by ST6Gal-I overexpression contributes to ovarian cancer cell migration and chemoresistance. *Mol. Med. Rep.* **2020**, *21*, 1449–1460. [[CrossRef](#)]
62. Santos, S.N.; Junqueira, M.S.; Francisco, G.; Vilanova, M.; Magalhães, A.; Baruffi, M.D.; Chammas, R.; Harris, A.L.; Reis, C.A.; Bernardes, E.S. O-glycan sialylation alters galectin-3 subcellular localization and decreases chemotherapy sensitivity in gastric cancer. *Oncotarget* **2016**, *7*, 83570–83587. [[CrossRef](#)]
63. Chen, X.; Wang, L.; Zhao, Y.; Yuan, S.; Wu, Q.; Zhu, X.; Niang, B.; Wang, S.; Zhang, J. ST6Gal-I modulates docetaxel sensitivity in human hepatocarcinoma cells via the p38 MAPK/caspase pathway. *Oncotarget* **2016**, *7*, 51955–51964. [[CrossRef](#)]
64. Patel, K.D.; De, M.; Jethva, D.D.; Rathod, B.S.; Patel, P.S. Alterations in Sialylation Patterns are Significantly Associated with Imatinib Mesylate Resistance in Chronic Myeloid Leukemia. *Arch. Med. Res.* **2022**, *53*, 51–58. [[CrossRef](#)]
65. Ma, H.; Zhou, H.; Song, X.; Shi, S.; Zhang, J.; Jia, L. Modification of sialylation is associated with multidrug resistance in human acute myeloid leukemia. *Oncogene* **2015**, *34*, 726–740. [[CrossRef](#)]
66. Yen, H.-Y.; Liu, Y.-C.; Chen, N.-Y.; Tsai, C.-F.; Wang, Y.-T.; Chen, Y.-J.; Hsu, T.-L.; Yang, P.-C.; Wong, C.-H. Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, 6955–6960. [[CrossRef](#)]
67. Natoni, A.; Farrell, M.L.; Harris, S.; Falank, C.; Kirkham-McCarthy, L.; Macauley, M.S.; Reagan, M.R.; O'dwyer, M. Sialyltransferase inhibition leads to inhibition of tumor cell interactions with E-selectin, VCAM1, and MADCAM1, and improves survival in a human multiple myeloma mouse model. *Haematologica* **2020**, *105*, 457–467. [[CrossRef](#)]
68. Lee, M.; Lee, H.J.; Bae, S.; Lee, Y.S. Protein sialylation by sialyltransferase involves radiation resistance. *Mol. Cancer Res.* **2008**, *6*, 1316–1325. [[CrossRef](#)]
69. Lee, M.; Lee, H.J.; Seo, W.D.; Park, K.H.; Lee, Y.S. Sialylation of integrin beta1 is involved in radiation-induced adhesion and migration in human colon cancer cells. *Int. J. Radiat. Oncol. Biol. Phys.* **2010**, *76*, 1528–1536. [[CrossRef](#)]
70. Park, J.J.; Lee, M. Increasing the alpha 2, 6 sialylation of glycoproteins may contribute to metastatic spread and therapeutic resistance in colorectal cancer. *Gut Liver* **2013**, *7*, 629–641. [[CrossRef](#)]
71. Punch, P.R.; Irons, E.E.; Manhardt, C.T.; Marathe, H.; Lau, J.T.Y. The sialyltransferase ST6GAL1 protects against radiation-induced gastrointestinal damage. *Glycobiology* **2020**, *30*, 446–453. [[CrossRef](#)]
72. Duarte, H.O.; Rodrigues, J.G.; Gomes, C.; Hensbergen, P.J.; Ederveen, A.L.H.; de Ru, A.H.; Mereiter, S.; Polónia, A.; Fernandes, E.; Ferreira, J.A.; et al. ST6Gal1 targets the ectodomain of ErbB2 in a site-specific manner and regulates gastric cancer cell sensitivity to trastuzumab. *Oncogene* **2021**, *40*, 3719–3733. [[CrossRef](#)]
73. Smithson, M.; Irwin, R.; Williams, G.; Alexander, K.L.; Smythies, L.E.; Nearing, M.; McLeod, M.C.; Al Diffalha, S.; Bellis, S.L.; Hardiman, K.M. Sialyltransferase ST6GAL-1 mediates resistance to chemoradiation in rectal cancer. *J. Biol. Chem.* **2022**, *298*, 101594. [[CrossRef](#)]
74. Butler, W.; McDowell, C.; Yang, Q.; He, Y.; Zhao, Y.; Hauck, J.S.; Zhou, Y.; Zhang, H.; Armstrong, A.J.; George, D.J.; et al. Rewiring of the N-Glycome with prostate cancer progression and therapy resistance. *npj Precis. Oncol.* **2023**, *7*, 22. [[CrossRef](#)]
75. Wen, R.; Zhao, H.; Zhang, D.; Chiu, C.-L.; Brooks, J.D. Sialylated glycoproteins as biomarkers and drivers of progression in prostate cancer. *Carbohydr. Res.* **2022**, *519*, 108598. [[CrossRef](#)]
76. Hartig, J.; Young, L.E.A.; Grimsley, G.; Mehta, A.S.; Ippolito, J.E.; Leach, R.J.; Angel, P.M.; Drake, R.R. The glycosylation landscape of prostate cancer tissues and biofluids. *Adv Cancer Res* **2024**, *161*, 1–30.
77. Scott, E.; Goode, E.A.; Garnham, R.; Hodgson, K.; Orozco-Moreno, M.; Turner, H.; Livermore, K.; Nangkana, K.P.; Frame, F.M.; Bermudez, A.; et al. ST6GAL1-mediated aberrant sialylation promotes prostate cancer progression. *J. Pathol.* **2023**, *261*, 71–84. [[CrossRef](#)]
78. Chakraborty, A.; Dorsett, K.A.; Trummell, H.Q.; Yang, E.S.; Oliver, P.G.; Bonner, J.A.; Buchsbaum, D.J.; Bellis, S.L. ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage. *J. Biol. Chem.* **2018**, *293*, 984–994. [[CrossRef](#)]
79. Smithson, M.; Al Diffalha, S.; Irwin, R.K.; Williams, G.; McLeod, M.C.; Somasundaram, V.; Bellis, S.L.; Hardiman, K.M. ST6GAL1 is associated with poor response to chemoradiation in rectal cancer. *Neoplasia* **2024**, *51*, 100984. [[CrossRef](#)]
80. Zhang, M.; Qi, T.; Yang, L.; Kolarich, D.; Heisterkamp, N. Multi-Faceted Effects of ST6Gal1 Expression on Precursor B-Lineage Acute Lymphoblastic Leukemia. *Front. Oncol.* **2022**, *12*, 828041. [[CrossRef](#)]
81. Liu, Q.; Ma, H.; Sun, X.; Liu, B.; Xiao, Y.; Pan, S.; Zhou, H.; Dong, W.; Jia, L. The regulatory ZFAS1/miR-150/ST6GAL1 crosstalk modulates sialylation of EGFR via PI3K/Akt pathway in T-cell acute lymphoblastic leukemia. *J. Exp. Clin. Cancer Res.* **2019**, *38*, 199. [[CrossRef](#)]

82. Heise, T.; Pijnenborg, J.F.A.; Büll, C.; van Hilten, N.; Kers-Rebel, E.D.; Balneger, N.; Elferink, H.; Adema, G.J.; Boltje, T.J. Potent Metabolic Sialylation Inhibitors Based on C-5-Modified Fluorinated Sialic Acids. *J. Med. Chem.* **2019**, *62*, 1014–1021. [[CrossRef](#)]
83. Moons, S.J.; Rossing, E.; Janssen, M.A.C.H.; Heise, T.; Büll, C.; Adema, G.J.; Boltje, T.J. Structure-Activity Relationship of Metabolic Sialic Acid Inhibitors and Labeling Reagents. *ACS Chem. Biol.* **2022**, *17*, 590–597. [[CrossRef](#)]
84. Munkley, J.; Li, L.; Krishnan, S.R.G.; Hysenaj, G.; Scott, E.; Dalglish, C.; Oo, H.Z.; Maia, T.M.; Cheung, K.; Ehrmann, I.; et al. Androgen-regulated transcription of ESRP2 drives alternative splicing patterns in prostate cancer. *Elife* **2019**, *8*, e47678. [[CrossRef](#)]
85. Kregel, S.; Chen, J.L.; Tom, W.; Krishnan, V.; Kach, J.; Brechka, H.; Fessenden, T.B.; Isikbay, M.; Paner, G.P.; Szmulewitz, R.Z.; et al. Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer. *Oncotarget* **2016**, *7*, 26259–26274. [[CrossRef](#)]
86. Scott, E.; Hodgson, K.; Calle, B.; Turner, H.; Cheung, K.; Bermudez, A.; Marques, F.J.G.; Pye, H.; Yo, E.C.; Islam, K.; et al. Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth. *Oncogene* **2023**, *42*, 926–937. [[CrossRef](#)]
87. Munkley, J.; Vodak, D.; Livermore, K.E.; James, K.; Wilson, B.T.; Knight, B.; McCullagh, P.; Mcgrath, J.; Crundwell, M.; Harries, L.W.; et al. Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability. *EBioMedicine* **2016**, *8*, 103–116. [[CrossRef](#)]
88. Wei, A.; Fan, B.; Zhao, Y.; Zhang, H.; Wang, L.; Yu, X.; Yuan, Q.; Yang, D.; Wang, S. ST6Gal-I overexpression facilitates prostate cancer progression via the PI3K/Akt/GSK-3 β /beta-catenin signaling pathway. *Oncotarget* **2016**, *7*, 65374–65388. [[CrossRef](#)]
89. Garnham, R.; Scott, E.; Livermore, K.E.; Munkley, J. ST6GAL1: A key player in cancer. *Oncol. Lett.* **2019**, *18*, 983–989.
90. Gc, S.; Bellis, S.L.; Hjelmeland, A.B. ST6Gal1: Oncogenic signaling pathways and targets. *Front. Mol. Biosci.* **2022**, *9*, 962908. [[CrossRef](#)]
91. Bojar, D.; Meche, L.; Meng, G.; Eng, W.; Smith, D.F.; Cummings, R.D.; Mahal, L.K. A Useful Guide to Lectin Binding: Machine-Learning Directed Annotation of 57 Unique Lectin Specificities. *ACS Chem. Biol.* **2022**, *17*, 2993–3012. [[CrossRef](#)] [[PubMed](#)]
92. Korenchuk, S.; Lehr, J.E.; McLean, L.; Lee, Y.G.; Whitney, S.; Vessella, R.; Lin, D.L.; Pienta, K.J. VCaP, a cell-based model system of human prostate cancer. *In Vivo* **2001**, *15*, 163–168.
93. Horoszewicz, J.S.; Leong, S.S.; Kawinski, E.; Karr, J.P.; Rosenthal, H.; Chu, T.M.; Mirand, E.A.; Murphy, G.P. LNCaP model of human prostatic carcinoma. *Cancer Res.* **1983**, *43*, 1809–1818. [[PubMed](#)]
94. Davis, I.D.; Martin, A.J.; Stockler, M.R.; Begbie, S.; Chi, K.N.; Chowdhury, S.; Coskinas, X.; Frydenberg, M.; Hague, W.E.; Horvath, L.G.; et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. *N. Engl. J. Med.* **2019**, *381*, 121–131. [[CrossRef](#)] [[PubMed](#)]
95. Culig, Z. Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer. *Curr. Mol. Biol. Rep.* **2017**, *3*, 230–235. [[CrossRef](#)]
96. Prekovic, S.; van den Broeck, T.; Linder, S.; van Royen, M.E.; Houtsmuller, A.B.; Handle, F.; Joniau, S.; Zwart, W.; Claessens, F. Molecular underpinnings of enzalutamide resistance. *Endocr. Relat. Cancer* **2018**, *25*, R545–R557. [[CrossRef](#)] [[PubMed](#)]
97. Dorsett, K.A.; Marciel, M.P.; Hwang, J.; E Ankenbauer, K.; Bhalerao, N.; Bellis, S.L. Regulation of ST6GAL1 sialyltransferase expression in cancer cells. *Glycobiology* **2021**, *31*, 530–539. [[CrossRef](#)]
98. Gc, S.; Tuy, K.; Rickenbacker, L.; Jones, R.; Chakraborty, A.; Miller, C.R.; Beierle, E.A.; Hanumanthu, V.S.; Tran, A.N.; Mobley, J.A.; et al. α 2,6 Sialylation mediated by ST6GAL1 promotes glioblastoma growth. *J. Clin. Investig.* **2022**, *7*, 158799. [[CrossRef](#)]
99. Pearce, O.M.; Laubli, H. Sialic acids in cancer biology and immunity. *Glycobiology* **2016**, *26*, 111–128. [[CrossRef](#)]
100. Britain, C.M.; Holdbrooks, A.T.; Anderson, J.C.; Willey, C.D.; Bellis, S.L. Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death. *J. Ovarian Res.* **2018**, *11*, 12. [[CrossRef](#)]
101. Cerasuolo, M.; Maccarinelli, F.; Coltrini, D.; Mahmoud, A.M.; Marolda, V.; Ghedini, G.C.; Rezzola, S.; Giacomini, A.; Triggiani, L.; Kostrzewa, M.; et al. Modeling Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in the TRAMP Model of Prostate Cancer. *Cancer Res.* **2020**, *80*, 1564–1577. [[CrossRef](#)]
102. Al Saoud, R.; Hamrouni, A.; Idris, A.; Mousa, W.K.; Izneid, T.A. Recent advances in the development of sialyltransferase inhibitors to control cancer metastasis: A comprehensive review. *Biomed Pharmacother* **2023**, *165*, 115091. [[CrossRef](#)]
103. Büll, C.; Brok, M.H.D.; Adema, G.J. Sweet escape: Sialic acids in tumor immune evasion. *Biochim. Biophys. Acta (BBA)-Rev. Cancer* **2014**, *1846*, 238–246. [[CrossRef](#)]
104. Zhou, X.; Chi, K.; Zhang, C.; Liu, Q.; Yang, G. Sialylation: A Cloak for Tumors to Trick the Immune System in the Microenvironment. *Biology* **2023**, *12*, 832. [[CrossRef](#)]
105. Macauley, M.S.; Crocker, P.R.; Paulson, J.C. Siglec-mediated regulation of immune cell function in disease. *Nat. Rev. Immunol.* **2014**, *14*, 653–666. [[CrossRef](#)]
106. Lim, J.; Sari-Ak, D.; Bagga, T. Siglecs as Therapeutic Targets in Cancer. *Biology* **2021**, *10*, 1178. [[CrossRef](#)]
107. Long, X.; Hou, H.; Wang, X.; Liu, S.; Diao, T.; Lai, S.; Hu, M.; Zhang, S.; Liu, M.; Zhang, H. Immune signature driven by ADT-induced immune microenvironment remodeling in prostate cancer is correlated with recurrence-free survival and immune infiltration. *Cell Death Dis.* **2020**, *11*, 779. [[CrossRef](#)]
108. Gamat-Huber, M.; McNeel, D.G. Androgen deprivation and immunotherapy for the treatment of prostate cancer. *Endocr.-Relat. Cancer* **2017**, *24*, T297–T310. [[CrossRef](#)]

109. Garnham, R.; Geh, D.; Nelson, R.; Ramon-Gil, E.; Wilson, L.; Schmidt, E.N.; Walker, L.; Adamson, B.; Buskin, A.; Hepburn, A.C.; et al. ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer. *Commun Biol.* **2024**, *7*, 276. [[CrossRef](#)]
110. Berois, N.; Pittini, A.; Osinaga, E. Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives. *Cancers* **2022**, *14*, 645. [[CrossRef](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.